ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Excerpt from the Press Release:

CARLSBAD, Calif. and BRISBANE, Australia, Oct. 4, 2022 /PRNewswire/ — ImpediMed Limited (ASX.IPD) is pleased to announce the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare. The pilot program will consist of an initial roll out of five (5) SOZO^® units to establish lymphedema screening services for breast cancer patients in centers across the United States. These units are scheduled to be installed over the coming quarter. Upon successful completion of the pilot program, GenesisCare will evaluate a staged expansion to additional sites in the United States and globally.

GenesisCare is a global care leader with more than 6,000 highly trained healthcare professionals employed at more than 300 locations across four countries. They are the one of largest providers of cancer care in USA, Australia, Spain, and the UK. In the US, GenesisCare operates radiation oncology treatment centers and integrated medical offices, including 120 radiation oncology centers. Additionally, GenesisCare operates a further 40 centers in Australia, 17 in Spain, and 14 in the UK.

GenesisCare focuses on a culture of care that is patient focused and performance driven. Their vision is to provide care that focuses on the individual as well as the condition. They personalize treatment by designing individualized care experiences that get the best possible life outcomes with a goal of delivering exceptional service in a way that enhances every aspect of a patient’s cancer journey.

Click the button below to read the entire Press Release:

Continue Reading The Press Release